Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $471.75 -0.10 (-0.02%) 6:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?

by Zacks Equity Research

Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.

    Zacks Equity Research

    Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel

    by Zacks Equity Research

    Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel

      Zacks Equity Research

      Boston Scientific Grows on Acquisitions, Product Launches

      by Zacks Equity Research

      Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.

        Tracey Ryniec headshot

        How to Invest in the Hot Medical Device Innovators

        by Tracey Ryniec

        Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.

          Zacks Equity Research

          Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm

          by Zacks Equity Research

          Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.

            Zacks Equity Research

            Stryker's HyperBranch Buyout to Boost Neurotechnology Business

            by Zacks Equity Research

            Stryker's (SYK) craniomaxillofacial division's market prospects bright.

              Zacks Equity Research

              Here's Why You Should Invest in CVS Health (CVS) Stock Now

              by Zacks Equity Research

              CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.

                Zacks Equity Research

                Here's Why You Should Buy Inogen (INGN) Stock Right Now

                by Zacks Equity Research

                Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.

                  Zacks Equity Research

                  Henry Schein's 3 Investments to Fortify Dental Implant Arm

                  by Zacks Equity Research

                  Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.

                    Zacks Equity Research

                    Quest Diagnostics Plans a Buyout to Widen TB Testing Suite

                    by Zacks Equity Research

                    Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.

                      Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical

                        Zacks Equity Research

                        STERIS (STE) Strategic Growth Strong Amid Several Headwinds

                        by Zacks Equity Research

                        STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.

                          Mark Vickery headshot

                          Top Research Reports for Alphabet, Bank of America & PepsiCo

                          by Mark Vickery

                          Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Bank of America (BAC), and PepsiCo (PEP).

                            Zacks Equity Research

                            Quest Diagnostics Inks Lab Service Deal With ReproSource

                            by Zacks Equity Research

                            Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.

                              Zacks Equity Research

                              Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp

                              by Zacks Equity Research

                              Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.

                                Zacks Equity Research

                                Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm

                                by Zacks Equity Research

                                Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.

                                  Zacks Equity Research

                                  Here's Why You Should Add Edwards Lifesciences Right Away

                                  by Zacks Equity Research

                                  We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.

                                    Zacks Equity Research

                                    Will LabCorp's (LH) Food Solution Divestment Upset Sales?

                                    by Zacks Equity Research

                                    LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.

                                      Zacks Equity Research

                                      Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1

                                      by Zacks Equity Research

                                      Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.

                                        Zacks Equity Research

                                        Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

                                        by Zacks Equity Research

                                        Is (ISRG) Outperforming Other Medical Stocks This Year?

                                          Zacks Equity Research

                                          Here's Why You Should Invest in Walgreens Boots Stock Now

                                          by Zacks Equity Research

                                          Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.

                                            Zacks Equity Research

                                            Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite

                                            by Zacks Equity Research

                                            Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.

                                              Zacks Equity Research

                                              Intuitive Surgical and InTouch Collaborate for IoMT Services

                                              by Zacks Equity Research

                                              Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.

                                                Zacks Equity Research

                                                Here's Why You Should Buy Intuitive Surgical (ISRG) Now

                                                by Zacks Equity Research

                                                Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.

                                                  Zacks Equity Research

                                                  Medtronic to Buy Mazor Robotics for Robotic Spine Surgery

                                                  by Zacks Equity Research

                                                  The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.